Abstract:Background: Artificial intelligence as a medical device (AIaMD) has the potential to transform many aspects of ophthalmic care, such as improving accuracy and speed of diagnosis, addressing capacity issues in high-volume areas such as screening, and detecting novel biomarkers of systemic disease in the eye (oculomics). In order to ensure that such tools are safe for the target population and achieve their intended purpose, it is important that these AIaMD have adequate clinical evaluation to support any regulatory decision. Currently, the evidential requirements for regulatory approval are less clear for AIaMD compared to more established interventions such as drugs or medical devices. There is therefore value in understanding the level of evidence that underpins AIaMD currently on the market, as a step toward identifying what the best practices might be in this area. In this systematic scoping review, we will focus on AIaMD that contributes to clinical decision-making (relating to screening, diagnosis, prognosis, and treatment) in the context of ophthalmic imaging. Objective: This study aims to identify regulator-approved AIaMD for ophthalmic imaging in Europe, Australia, and the United States; report the characteristics of these devices and their regulatory approvals; and report the available evidence underpinning these AIaMD. Methods: The Food and Drug Administration (United States), the Australian Register of Therapeutic Goods (Australia), the Medicines and Healthcare products Regulatory Agency (United Kingdom), and the European Database on Medical Devices (European Union) regulatory databases will be searched for ophthalmic imaging AIaMD through a snowballing approach. PubMed and clinical trial registries will be systematically searched, and manufacturers will be directly contacted for studies investigating the effectiveness of eligible AIaMD. Preliminary regulatory database searches, evidence searches, screening, data extraction, and methodological quality assessment will be undertaken by 2 independent review authors and arbitrated by a third at each stage of the process. Results: Preliminary searches were conducted in February 2023. Data extraction, data synthesis, and assessment of methodological quality commenced in October 2023. The review is on track to be completed and submitted for peer review by April 2024. Conclusions: This systematic review will provide greater clarity on ophthalmic imaging AIaMD that have achieved regulatory approval as well as the evidence that underpins them. This should help adopters understand the range of tools available and whether they can be safely incorporated into their clinical workflow, and it should also support developers in navigating regulatory approval more efficiently. International registered report identifier (irrid): DERR1-10.2196/52602.

How medical AI devices are evaluated: limitations and recommendations from an analysis of FDA approvals

FDA-Approved Artificial Intelligence and Machine Learning (AI/ML)-Enabled Medical Devices: An Updated Landscape

Not all AI health tools with regulatory authorization are clinically validated

Approval of artificial intelligence and machine learning-based medical devices in the USA and Europe (2015–20): a comparative analysis

How AI challenges the medical device regulation: patient safety, benefits, and intended uses

Regulating AI Adaptation: An Analysis of AI Medical Device Updates

Artificial intelligence in medical device software and high-risk medical devices – a review of definitions, expert recommendations and regulatory initiatives

Regulatory responses and approval status of artificial intelligence medical devices with a focus on China

Health Disparities and Reporting Gaps in Artificial Intelligence (AI) Enabled Medical Devices: A Scoping Review of 692 U.S. Food and Drug Administration (FDA) 510k Approvals

Artificial Intelligence in Breast Cancer Screening: Evaluation of FDA Device Regulation and Future Recommendations

Systematic analysis of the test design and performance of AI/ML-based medical devices approved for triage/detection/diagnosis in the USA and Japan

A scoping review of reporting gaps in FDA-approved AI medical devices

Data-Driven Analysis of AI in Medical Device Software in China: Deep Learning and General AI Trends Based on Regulatory Data

FDA Perspective on the Regulation of Artificial Intelligence in Health Care and Biomedicine.

The current status and future of FDA-approved artificial intelligence tools in chest radiology in the United States

Technology-Enabled, Evidence-Driven, and Patient-Centered: The Way Forward for Regulating Software as a Medical Device

AI in imaging: the regulatory landscape

AI as a Medical Device for Ophthalmic Imaging in Europe, Australia, and the United States: Protocol for a Systematic Scoping Review of Regulated Devices

FDA Review of Radiologic AI Algorithms: Process and Challenges

The need for a system view to regulate artificial intelligence/machine learning-based software as medical device

A Review of Biomedical Devices: Classification, Regulatory Guidelines, Human Factors, Software as a Medical Device, and Cybersecurity